MPI’s Drug Master File (DMF)

A Drug Master File (DMF) is a confidential document submitted to the U.S. Food and Drug Administration (FDA) containing detailed information about facilities, processes, or articles used in the manufacturing process, packaging, and storing of one or more human drugs. This is crucial in the regulatory process as it allows for a comprehensive review of the drug product, ensuring that it meets all the necessary regulatory requirements for safety, quality, and efficacy.

The FDA plays a pivotal role in reviewing and accepting DMFs. This process is integral in the clinical development and drug evaluation phases, especially for new drugs and investigational new drug applications. The acceptance and review process of a DMF by the FDA signifies a validation of the quality control and manufacturing processes involved in drug production, thereby confirming adherence to the highest standards of regulatory affairs and pharmaceutical compliance.

Medical Packaging Inc., LLC (MPI) has proudly achieved a milestone with the original submission and acceptance of a Type III Drug Master File. This specific DMF number relates to packaging materials, underscoring MPI’s commitment to excellence in pharmaceutical packaging. We disclosed every packaging material, component, intended usage, as well as manufacturer information to demonstrate our product quality.

Having our own DMF means MPI can now provide more direct and efficient support to our customers. This eliminates reliance on third-party vendors for critical regulatory and technical documentation and additional information, reducing potential delays in FDA filings. By streamlining the process, we ensure that our customers can focus more on their core activities like clinical trials, drug development, and marketing authorization without the added regulatory burden.

For a specialty pharmaceutical company, manufacturers, or CDMO, MPI’s DMF signifies our ability to meet the stringent requirements for FDA-compliant liquid cup packaging, essential for lower-volume, high-value medicinal products.

Elevating Industry Standards

The acceptance of MPI’s Drug Master File (DMF) by the U.S. Food and Drug Administration marks a significant milestone in our ongoing commitment to excellence in pharmaceutical packaging and labeling. This achievement not only highlights our dedication to maintaining the highest standards of quality and compliance but also positions MPI as a regulatory authority in the pharmaceutical packaging industry.

Strengthening Customer Partnerships

With our own DMF, MPI now holds a strategic advantage in supporting our clients’ needs with greater efficiency and reliability. This translates into an enhanced trust and partnership with our clients, allowing them to navigate the complex landscape of drug administration and regulatory requirements with greater ease and confidence.

Accelerating Market Access

As DMF holders, MPI provides expedited support in the New Drug Application (NDA) or Abbreviated New Drug Filing (ANDA) processes for our clients. This capability is critical in the pharmaceutical industry, where speed to market can significantly impact the success and accessibility of new medicinal products. By reducing the regulatory burden on our clients, MPI plays a pivotal role in bringing vital medications to market more swiftly and safely.

Upholding Intellectual Property and Confidential Information

The DMF process respects the confidentiality of proprietary information, allowing MPI to protect our intellectual property while sharing necessary data with the FDA. This balance of transparency and protection is crucial in fostering innovation and trust within the pharmaceutical sector.

As Medical Packaging Inc., LLC continues to evolve and grow, the DMF is more than just a certification; it is a testament to our unwavering commitment to quality, safety, and regulatory excellence. We are proud to lead the way in providing innovative, FDA-compliant packaging solutions, contributing to the advancement of healthcare and patient well-being in the United States.

Center for Drug Evaluation and Research. “Drug Master Files: Guidelines.” U.S. Food and Drug Administration, FDA, www.fda.gov/drugs/guidances-drugs/drug-master-files-guidelines. Accessed 11 Dec. 2023.